News

FDA has removed the clinical hold from Aastrom’ US phase-II Impact-Dcm clinical trial. Patient enrollment would resume at all five initiated clinical sites. The Impact-Dcm trial is evaluating

Vical is proceeding with the development of the RapidResponse platform under the third year of grant funding, awarded by the National Institute of Allergy and Infectious Diseases (NIAID).

Cephalon has provided results from a pivotal clinical trial of lestaurtinib (CEP-701), in patients with relapsed acute myelogenous leukemia (AML). Lestaurtinib is a potent inhibitor of several tyrosine

Oculus Innovative (Oculus) has reported preliminary results from its US 40-patient feasibility study, for the treatment of acne with Microcyn hydrogel formulation Cheryl Bongiovanni, Director, Lakes Aesthetics Center,

The Mayo Clinic has reported data on a prostate cancer study with ipilimumab, a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule

BioLine has announced the initiation of phase I/II clinical trial aimed at assessing the safety and efficacy of BL-5010, a novel formulation for the non surgical removal of

Forest Laboratories has provided positive results from two global multi-center phase-III studies of ceftaroline, for the treatment of community-acquired bacterial pneumonia (CABP). The top-line data in each of

KV Pharmaceutical has signed an agreement with Gedeon Richter, USA for licensing rights to some of KV’ technologies and products in Women’s Health. Under this agreement, Gedeon Richter

Non-GAAP adjusted earnings from continuing operation per ADS increased by about 80% year-over-year to about RMB15.8 for fiscal 2008. For the fourth quarter of fiscal 2008, Revenues from